AAPL289.36+7.62 (+2.70%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|AAPL289.36+7.62 (+2.70%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|
24.7 C
New York
Wednesday, July 1, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

Abcentra Announces Appointment of Dr. Peter Libby as a Board Member as it Enters Orticumab’s Phase 2b Trial (FORTIFY)

LOS ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today announced the appointment...

Sterotherapeutics Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating ST-002 for Cushing’s Syndrome

DOYLESTOWN, Pa., June 24, 2025 /PRNewswire/ -- Sterotherapeutics LLC, a clinical-stage biopharmaceutical company focused on rare endocrine diseases, today announced that the first patient...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

TKSoftware Inc. Unveils ICONIC Pro: The All-In-One Medical Billing & Clearinghouse Solution

TKSoftware Inc. today launches ICONIC Pro, a unified, cloud–based platform that combines claims submission, electronic remittance, eligibility verification, and claims scrubbing—designed to simplify revenue...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Apollo Provides $750 Million High Grade Capital Solution to Mumbai International Airport Ltd. in Second Transaction

Investment Grade Financing Supports Critical Indian Infrastructure Asset 
Investment Grade Financing Supports Critical Indian Infrastructure Asset

Lysander Funds Limited Announces Management Fee Reductions, Change in Portfolio Manager and Change in Risk Ratings for Certain Funds

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Lysander Funds Limited (“Lysander”) announced today management fee reductions, change in portfolio manager and change in risk ratings for certain of its mutual funds.  Details of these changes are set out below.

Lysander Funds Limited annonce des réductions des frais de gestion, le remplacement d’un gestionnaire de portefeuille et la modification du niveau de risque de...

TORONTO, 23 juin 2025 (GLOBE NEWSWIRE) -- Lysander Funds Limited (« Lysander ») a annoncé aujourd’hui des réductions des frais de gestion, le remplacement d’un gestionnaire de portefeuille et la modification du niveau de risque de certains de ses organismes de placement collectif (OPC). Des détails sur ces changements sont donnés ci-après.

Medscape Establishes Dedicated Presence in Australia to Support Healthcare Innovation

LONDON, June 24, 2025 /PRNewswire/ -- Medscape, a leading provider of medical news, education, and resources for healthcare professionals, is proud to announce the...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers